SIGA Technologies 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12345678910111213»
  • ||||||||||  TPOXX (tecovirimat) / SIGA Technologies
    Journal:  In Silico Repurposed Drugs against Monkeypox Virus. (Pubmed Central) -  Sep 3, 2022   
    Currently, the US Food and Drug Administration (FDA) approved poxvirus treatment involves the use of tecovirimat...In this study, virtual screening and molecular dynamics were employed to explore the potential repurposing of multiple drugs previously approved by the FDA or other jurisdictions for other applications. Several drugs are predicted to tightly bind to viral proteins, which are crucial in viral replication, including molecules which show high potential for binding the monkeypox D13L capsid protein, whose inhibition has previously been demonstrated to suppress viral replication.
  • ||||||||||  ACAM2000 (smallpox (vaccinia) live vaccine) / Emergent Biosolutions, Vistide (cidofovir) / Gilead, TPOXX (tecovirimat) / SIGA Technologies
    Review, Journal:  Vaccination for Monkeypox Virus Infection in Humans: A Review of Key Considerations. (Pubmed Central) -  Aug 27, 2022   
    Two effective vaccines exist for the prevention of MVIH: modified vaccinia Ankara and ACAM2000...Priority groups for vaccination should include healthcare workers at high risk for occupational exposure, immunocompromised patients, and children. Vaccination strategies include pre-exposure vaccination, post-exposure prophylaxis, and ring vaccination of close contacts.
  • ||||||||||  Tembexa (brincidofovir oral) / SymBio Pharma, TPOXX (tecovirimat) / SIGA Technologies
    Journal:  Monkeypox and its pandemic potential: what the anaesthetist should know. (Pubmed Central) -  Aug 25, 2022   
    Vaccination strategies include pre-exposure vaccination, post-exposure prophylaxis, and ring vaccination of close contacts. No abstract available
  • ||||||||||  Imvanex (live modified vaccinia virus ankara) / Bavarian Nordic, TPOXX (tecovirimat) / SIGA Technologies
    Journal:  Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection - United States, August 2022. (Pubmed Central) -  Aug 22, 2022   
    No identified drug interactions would preclude coadministration of tecovirimat with antiretroviral therapy (ART) for HIV infection...Although data are limited for monkeypox in patients with HIV, prompt diagnosis, treatment, and prevention might reduce the risk for adverse outcomes and limit monkeypox spread. Prevention and treatment considerations will be updated as more information becomes available.
  • ||||||||||  Journal:  MONKEYPOX AND PREGNANCY: FORECASTING THE RISKS. (Pubmed Central) -  Aug 21, 2022   
    Obstetric concerns relating to antiviral therapy with tecovirimat and vaccinia immune globulin, including the risks of QTc prolongation, erroneous blood glucose monitoring and venous thromboembolism, are highlighted. Finally, we discuss the possibility of monkeypox vaccine hesitancy during pregnancy, offer strategies to mitigate these risks and propose research priorities to address knowledge gaps about the impact of monkeypox infection on maternal, fetal, and neonatal health.
  • ||||||||||  TPOXX (tecovirimat) / SIGA Technologies
    Journal:  Human Monkeypox Disease. (Pubmed Central) -  Aug 14, 2022   
    Antiviral therapy has been advocated, of which tecovirimat is promising in patients with co-morbidities. Vaccines will be the mainstay for the present and future control of the disease.
  • ||||||||||  TPOXX (tecovirimat) / SIGA Technologies
    Journal:  Tecovirimat for the Treatment of Human Monkeypox: An Initial Series From Massachusetts, United States. (Pubmed Central) -  Aug 13, 2022   
    Therapeutics for the treatment of smallpox, a related Orthopoxvirus, may be used and affect the natural history of monkeypox. We present 3 patients from our hospitals treated with tecovirimat, a pan-Orthopoxvirus inhibitor currently available under an expanded access investigational new drug protocol for monkeypox.